CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Revenue | ||||
| Total Revenue | $ 485,385 | $ 118,146 | $ 661,660 | $ 189,910 |
| Cost of Revenue | ||||
| Total Cost of Revenue | 202,805 | 92,223 | 311,503 | 149,935 |
| Gross Profit | 282,580 | 25,923 | 350,157 | 39,975 |
| Operating Expenses | ||||
| General and administrative | 23,175 | 40,494 | 56,952 | 72,412 |
| Advertising and promotion | 22,436 | 9,663 | 59,443 | 31,185 |
| Clinical trial fees | 7,175 | 0 | 12,025 | 0 |
| Corporate filing fees | 7,723 | 0 | 11,728 | 0 |
| Equipment leases | 6,696 | 4,464 | 13,392 | 11,160 |
| Legal and professional fees | 81,922 | 46,000 | 160,731 | 93,814 |
| Public relations | 2,480 | 0 | 4,920 | 0 |
| Repairs and maintenance | 1,152 | 0 | 2,162 | 0 |
| Rent | 19,748 | 16,130 | 35,931 | 32,002 |
| Research and development | 0 | 24,616 | 0 | 24,616 |
| Salaries and wages | 55,129 | 0 | 87,731 | 0 |
| Utilities | 1,672 | 0 | 2,538 | 0 |
| Depreciation and amortization | 1,443 | 1,143 | 2,695 | 1,916 |
| Total Operating Expenses | 230,751 | 142,510 | 450,248 | 267,105 |
| Income (Loss) from Operations | 51,829 | (116,587) | (100,091) | (227,130) |
| Other Income (Expense) | ||||
| Interest income | 375 | 0 | 750 | 0 |
| Interest expense – related party | (11,786) | (7,410) | (22,766) | (13,086) |
| Total Other Income (Expense) | (11,411) | (7,410) | (22,016) | (13,086) |
| Net Income (Loss) Before provision for Income Taxes | 40,418 | (123,997) | (122,107) | (240,216) |
| Provision for Income Taxes | 0 | 0 | 0 | 0 |
| NET INCOME (LOSS) | $ 40,418 | $ (123,997) | $ (122,107) | $ (240,216) |
| Net Income (Loss) Per Share: Basic | $ (0.00) | $ (0.00) | $ (0.00) | $ (0.00) |
| Net Income (Loss) Per Share: Diluted | $ 0.00 | $ 0 | $ 0 | $ 0 |
| Weighted Average Number of Shares Outstanding: Basic | 94,404,696 | 89,641,758 | 94,404,696 | 92,770,810 |
| Weighted Average Number of Shares Outstanding: Diluted | 161,404,696 | 89,641,758 | 94,404,696 | 92,770,810 |
| Sales Of Supplements [Member] | ||||
| Revenue | ||||
| Total Revenue | $ 0 | $ 1,091 | $ 0 | $ 2,155 |
| Medical Procedures [Member] | ||||
| Revenue | ||||
| Total Revenue | 329,820 | 26,000 | 434,670 | 96,700 |
| Sales Of Biologics [Member] | ||||
| Revenue | ||||
| Total Revenue | 151,750 | 87,500 | 221,525 | 87,500 |
| Services [Member] | ||||
| Revenue | ||||
| Total Revenue | 0 | 2,267 | 0 | 2,267 |
| Shipping And Delivery [Member] | ||||
| Revenue | ||||
| Total Revenue | 3,815 | 1,288 | 5,465 | 1,288 |
| Supplements [Member] | ||||
| Cost of Revenue | ||||
| Total Cost of Revenue | 0 | 188 | 0 | 663 |
| Procedures [Member] | ||||
| Cost of Revenue | ||||
| Total Cost of Revenue | 82,588 | 13,551 | 153,550 | 70,788 |
| Biologics [Member] | ||||
| Cost of Revenue | ||||
| Total Cost of Revenue | $ 120,217 | $ 78,484 | $ 157,953 | $ 78,484 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses. No definition available.
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of general expenses not normally included in Other Operating Costs and Expenses. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of operating expense of regulated operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|